In today’s briefing:
- Actinogen Medical — XanaMIA study enrols 100th patient
- AustralianSuper now onboard with Wrkr
Actinogen Medical — XanaMIA study enrols 100th patient
Actinogen Medical announced on 30 June that it has recruited the 100th patient for its ongoing XanaMIA Phase IIb/III study assessing lead candidate Xanamem (emestedastat) in patients with biomarker-positive Alzheimer’s disease (AD). The company is on track to report a pre-planned interim efficacy (futility) analysis in early Q126, which, if successful, should strengthen confidence in the AD programme. After rolling forward our estimates, we obtain a total equity valuation of A$724.6m (versus A$673.8m previously).
AustralianSuper now onboard with Wrkr
- Wrkr Ltd (ASX:WRK) offers compliance solutions for Australian superannuation contributions and payroll including member onboarding, super payments, messaging and employee validation.
- WRK in conjunction with MUFG has been selected to deliver a comprehensive digital platform across clearing house, gateway and digital employer services to enhance AustralianSuper’s efficiency and compliance in superannuation administration.
- AustralianSuper has ~3.5m members, and we estimate half (~1.7m) are active.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
